Agomab Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
72
- Stock Symbol
-
AGMB
- Investments
-
1
- Share Price
-
$5.44
- (As of Friday Closing)
Agomab Therapeutics General Information
Description
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
Contact Information
Website
www.agomab.comCorporate Office
- Posthoflei 1/6
- 2600 Antwerp
- Belgium
Corporate Office
- Posthoflei 1/6
- 2600 Antwerp
- Belgium
Agomab Therapeutics Timeline
Agomab Therapeutics Stock Performance
As of 20-Nov-2026, Agomab Therapeutics’s stock price is $5.44. Its current market cap is $268M with 49.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.44 | $5.62 | $5.39 - $17.82 | $268M | 49.2M | 207K | -$2.08 |
Agomab Therapeutics Financials Summary
As of 30-Jun-2026, Agomab Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 503,852 | |||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (82,529) | (72,054) | (50,970) | (13,119) |
| Net Income | (77,749) | (70,553) | (50,065) | (12,325) |
| Total Assets | 332,199 | 180,546 | 214,730 | 189,310 |
| Total Debt | 1,301 | 1,473 | 1,608 | 1,791 |
Agomab Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Agomab Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Agomab Therapeutics Comparisons
Industry
Financing
Details
Agomab Therapeutics Competitors (59)
One of Agomab Therapeutics’s 59 competitors is Cristal Therapeutics, a Venture Capital-Backed company based in Maastricht, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cristal Therapeutics | Venture Capital-Backed | Maastricht, Netherlands | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Abivax | Formerly PE-Backed | Paris, France |
Agomab Therapeutics Patents
Agomab Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026172014-A1 | Alk5 activity modulators | Pending | 17-Feb-2025 | ||
| WO-2026172015-A1 | Novel compounds | Pending | 17-Feb-2025 | ||
| WO-2026082960-A1 | 1,5-naphtyridine and quinoline based inhibitors of alk5 | Pending | 18-Oct-2024 | ||
| WO-2026082968-A1 | Novel compounds | Pending | 18-Oct-2024 | ||
| US-11834507-B2 | Anti-met agonist antibody for use in the treatment of colorectal cancer | Active | 03-Jan-2018 | C07K16/2863 |
Agomab Therapeutics Signals
Agomab Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Agomab Therapeutics Acquisitions (1)
Agomab Therapeutics’s most recent deal was a Merger/Acquisition with Origo Biopharma. The deal was made on 26-Oct-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Origo Biopharma | 26-Oct-2021 | Merger/Acquisition | Biotechnology |
Agomab Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Agomab Therapeutics FAQs
-
When was Agomab Therapeutics founded?
Agomab Therapeutics was founded in 2017.
-
Where is Agomab Therapeutics headquartered?
Agomab Therapeutics is headquartered in Antwerp, Belgium.
-
What is the size of Agomab Therapeutics?
Agomab Therapeutics has 72 total employees.
-
What industry is Agomab Therapeutics in?
Agomab Therapeutics’s primary industry is Drug Discovery.
-
Is Agomab Therapeutics a private or public company?
Agomab Therapeutics is a Public company.
-
What is Agomab Therapeutics’s stock symbol?
The ticker symbol for Agomab Therapeutics is AGMB.
-
What is the current stock price of Agomab Therapeutics?
As of 20-Nov-2026 the stock price of Agomab Therapeutics is $5.44.
-
What is the current market cap of Agomab Therapeutics?
The current market capitalization of Agomab Therapeutics is $268M.
-
Who are Agomab Therapeutics’s competitors?
Cristal Therapeutics, Ayala Pharmaceuticals, Adaptimmune Therapeutics, Sorrento Therapeutics, and Abivax are some of the 59 competitors of Agomab Therapeutics.
-
What is Agomab Therapeutics’s annual earnings per share (EPS)?
Agomab Therapeutics’s EPS for 12 months was -$2.08.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process